NCT00710411

Brief Summary

The purpose of this study is to determine the inflammatory response after multiple trauma in humans.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2009

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 2, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 4, 2008

Completed
9 months until next milestone

Study Start

First participant enrolled

April 1, 2009

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

December 17, 2015

Status Verified

December 1, 2015

Enrollment Period

6.5 years

First QC Date

July 2, 2008

Last Update Submit

December 16, 2015

Conditions

Keywords

humanspatientspolytraumacomplementinflammationinflammatory responsebiomarkerscytokinescell surface markersapoptosisNF-kappaBfunctional polymorphismsmesenchymal stem cellseverity of injuryISSinfectionssystemic inflammatory response syndromeSIRSsepsissevere sepsisshockorgan dysfunctionsSOFAseverity of diseaseAPACHEIISAPSIISPAPS3length of staywound healingoutcomemortality

Outcome Measures

Primary Outcomes (1)

  • Inflammatory pattern of complement activation, biomarkers and complement-regulating proteins (CRegs)on leukocytes

    0, 1, 4, 12, 24, 48, 96, 120 und 240 h after trauma

Secondary Outcomes (1)

  • inflammatory biomarkers, cell surface markers, apoptosis, functional polymorphisms, mesenchymal stem cells, severity of injury (ISS), infections, SIRS, sepsis, shock, organ dysfunctions, severity of disease, ICU length of stay, wound healing, mortality

    0, 1, 4, 12, 24, 48, 96, 120 und 240 h after trauma for biochemical and immunological parameters; ISS on admission; scores on a daily basis; ICU and hospital death on discharge

Study Arms (1)

A, 2

Polytraumatized patients with ISS \> 18 and healthy controls

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Polytraumatized patients with an ISS \> 18 Controls: healthy volunteers

You may qualify if:

  • multiple trauma injury, injury severity score (ISS) \> 18 with
  • isolated fractures of the extremities
  • fractures of the extremities combined with blunt/penetrating visceral trauma
  • fractures of the extremities combined with blunt/penetrating thoracic trauma
  • isolated head injury with morphological changes in CCT
  • combination of points 1 - 4

You may not qualify if:

  • life expectancy \< 24 hours
  • participation in other trials
  • ISS \< 18
  • cardiopulmonary reanimation on the accident scene or dying immediately after hospital admission
  • age \< 18 years
  • known or suspected pregnancy
  • patients with ray-treatment or chemotherapy within the last three months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinic of Anesthesiology and Clinic of Traumatology, Hand-, Plastic-, and Reconstructive Surgery

Ulm, 89070, Germany

Location

Related Publications (4)

  • Huber-Lang M, Denk S, Fulda S, Erler E, Kalbitz M, Weckbach S, Schneider EM, Weiss M, Kanse SM, Perl M. Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro. Mol Immunol. 2012 Feb;50(1-2):60-5. doi: 10.1016/j.molimm.2011.12.005. Epub 2012 Jan 14.

  • Unnewehr H, Rittirsch D, Sarma JV, Zetoune F, Flierl MA, Perl M, Denk S, Weiss M, Schneider ME, Monk PN, Neff T, Mihlan M, Barth H, Gebhard F, Ward PA, Huber-Lang M. Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J Immunol. 2013 Apr 15;190(8):4215-25. doi: 10.4049/jimmunol.1200534. Epub 2013 Mar 11.

  • Denk S, Wiegner R, Hones FM, Messerer DA, Radermacher P, Weiss M, Kalbitz M, Ehrnthaller C, Braumuller S, McCook O, Gebhard F, Weckbach S, Huber-Lang M. Early Detection of Junctional Adhesion Molecule-1 (JAM-1) in the Circulation after Experimental and Clinical Polytrauma. Mediators Inflamm. 2015;2015:463950. doi: 10.1155/2015/463950. Epub 2015 Oct 18.

  • Kozarcanin H, Lood C, Munthe-Fog L, Sandholm K, Hamad OA, Bengtsson AA, Skjoedt MO, Huber-Lang M, Garred P, Ekdahl KN, Nilsson B. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost. 2016 Mar;14(3):531-45. doi: 10.1111/jth.13208. Epub 2016 Feb 15.

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood, serum, white cells, and tissues will be retained.

MeSH Terms

Conditions

Multiple TraumaInflammationInfectionsSystemic Inflammatory Response SyndromeSepsisShock

Condition Hierarchy (Ancestors)

Wounds and InjuriesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Manfred M Weiss, MD, MBA

    Clinic of Anesthesiology, University Hospital Medical School, Steinhoevelstrasse 9, 89070 Ulm, Germany

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, MD, MBA

Study Record Dates

First Submitted

July 2, 2008

First Posted

July 4, 2008

Study Start

April 1, 2009

Primary Completion

October 1, 2015

Study Completion

December 1, 2015

Last Updated

December 17, 2015

Record last verified: 2015-12

Locations